Clinical Trial Update: A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) [Phase 3]

View source ↗

Summary

A Phase 3 multi-center trial evaluating onset and duration of action of AC-170 0.24% versus vehicle in the conjunctival allergen challenge has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• AC-170 0.24% (AC-170)

Snippet

Sponsor: Aciex Therapeutics, Inc. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2017-10-03